适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 216
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
This is clinical study to test, for the first time in people, the safety (anygood or bad effects), how long the drug can stay in the body and if it cancontrol the disease of people diagnosed with advanced cancer that has notresponded to treatment, has returned after it has been treated, or cannotbe treated by surgery, drugs, or any other known treatments.CTIS2023-509969-20-00Celgene Corp.133
招募中
1 期
A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytomaSurgically Resected Glioblastoma (GBM) or Astrocytoma with a Molecular Signature of Unmethylated GlioblastomaMedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10060971Term: Astrocytoma malignant Class: 100000004864CTIS2022-501423-25-00Curevac AG54
进行中（未招募）
1 期
ADME: A Study to Understand What the Body does to the Study Compound Called PF-07220060 When Taken by Healthy Adults.metastatic/advanced breast cancerMedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10072737Term: Advanced breast cancer Class: 10029104CTIS2023-507074-40-00Pfizer Inc.12
进行中（未招募）
1 期
A Phase 1, Dose Finding Study of CC-92328 in Subjects with Relapsedand/or Refractory Multiple Myeloma.MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104Multiple myelomaCTIS2023-505079-65-00Celgene Corp.4
招募中
1 期
A phase 1 study to assess the mass balance, pharmacokinetics, metabolism, and excretion of GSBR-1290, containing a microtracer dose of [14C] GSBR-1290, in healthy participantsot applicable - Healthy volonteersMedDRA version: 20.0Level: LLTClassification code: 10014697Term: Endocrine disorder NOS Class: 10014698CTIS2024-512578-83-00Structure Therapeutics Inc.8